A recent study published in European Urology suggests that patterns of treatment failure might help to predict what the next treatment should be for patients with metastatic renal cell carcinoma.
Renal Cell Carcinoma
A phase III study of adjuvant girentuximab in patients with high-risk clear cell RCC showed that the drug provided no clinical benefit compared with placebo.
Combining two cancer immunotherapies to target both the interleukin 10 (IL-10) and programmed cell death protein 1 (PD-1) receptors has yielded promising early results for some patients with renal cell carcinoma and non-small cell lung cancer.
A new class of agents known as hypoxia-inducible factors-2 inhibitors may be more effective and better tolerated than sunitinib (Sutent), the current standard of care, in patients with renal cell carcinoma.
Despite treatment advances for renal cell carcinoma, biomarkers are urgently needed for earlier diagnosis and treatment, and quicker assessment of treatment efficacy. Development of such tools has lagged behind biomarker research for more common cancers, and despite encouraging findings from several newly published preclinical studies.
The NCI is granting the University of Texas (UT) Southwestern Medical Center the Specialized Program of Research Excellence (SPORE) award worth $11 million to help advance new treatments.
Studies have demonstrated that renal cell carcinoma (RCC) positive for PD-L1 is more likely to respond to PD-1 pathway blockers compared to those patients who are negative for PD-L1.
Compared to everolimus, the oral tyrosine kinase inhibitor cabozantinib improves objective tumor response, delays disease progression, and prolongs overall survival time among patients with RCC.
Anti-programmed cell death protein 1 (PD-1) checkpoint inhibitor immunotherapy with nivolumab is safe and effective even after disease progression among patients with metastatic RCC.
Clinicians now have a new targeted therapy option for treating patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy.